Broxinac eye drops, 0.09%, 1.7 mL per dropper bottle

In stock: 1
$68.00

Ingredients

Active ingredient: bromfenac;

1 mL of eye drop solution contains 1.035 mg of bromfenac sodium sesquihydrate, equivalent to 0.9 mg of free bromfenic acid;

excipients: benzalkonium chloride, boric acid, disodium edetate, polysorbate 80, povidone K-30, sodium borate, anhydrous sodium sulfite (E 221), sodium hydroxide, water for injection.

Dosage Form

Eye drops.

Main physical and chemical properties: a clear, greenish-yellow solution.

Pharmacotherapeutic group

Nonsteroidal anti-inflammatory drugs.

ATC code S01B C11.

Pharmacological properties

Pharmacodynamics.

Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory and analgesic effects; it blocks the synthesis of prostaglandins from arachidonic acid by inhibiting cyclooxygenase 1 and 2, thereby reducing inflammation and the pain response.

In vivo studies have shown that prostaglandins are mediators of certain types of ocular inflammation. In animal studies, prostaglandins contributed to disruption of the blood-ocular barrier, increased vascular permeability, caused vasodilation and leukocytosis, and increased intraocular pressure.

Pharmacokinetics.

Absorption.

Bromfenac effectively penetrates the cornea: following a single instillation, the concentration in the aqueous humor is 79 ± 68 ng/mL 150–180 minutes after administration.

Distribution.

The concentration of the drug in blood plasma is significantly below the limit of detection and has no clinical significance.

The concentration mentioned above persists for 12 hours in the aqueous humor, with therapeutically significant concentrations maintained in ocular tissues, including the retina, for up to 24 hours.

Metabolism and excretion.

The half-life in the aqueous humor is approximately 1.4 hours.

Indications

Treatment:

  • postoperative inflammation and pain relief in patients following cataract extraction;
  • non-infectious inflammatory diseases of the anterior segment of the eye.

Contraindications

Hypersensitivity to any of the drug’s components, as well as to other nonsteroidal anti-inflammatory drugs.

The drug is contraindicated in patients who experience worsening bronchial asthma attacks, hives, or symptoms of acute rhinitis when taking acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs.

Use is contraindicated in patients under 18 years of age (the safety and efficacy of the drug in children have not been studied).

Interactions with Other Medications and Other Types of Interactions

This medication may be used concomitantly with other ophthalmic medications:

α-adrenomimetics, β-blockers, carbonic anhydrase inhibitors, cycloplegics, mydriatics, and antibiotics.

In such cases, the medications should be administered at least five minutes apart.

Special Instructions for Use

Excipients.

Sodium sulfite, which is contained in the drug, may cause an allergic reaction, including anaphylactic reactions and asthma attacks (including life-threatening ones) in susceptible individuals. Sensitivity to sulfites is increased in individuals with bronchial asthma and a history of allergic reactions.

The product contains benzalkonium chloride; therefore, close monitoring is necessary during frequent or prolonged use. Benzalkonium chloride is known to discolor soft contact lenses; therefore, contact with soft contact lenses should be avoided; causes eye irritation, punctate keratopathy, and/or toxic ulcerative keratopathy.

Nonsteroidal Anti-Inflammatory Drugs

The use of NSAIDs may slow the healing process, especially when used in combination with topical corticosteroids.

Patients should be advised that healing may be delayed while using NSAIDs.

Cross-sensitivity.

When using Broxinac, there is a risk of developing cross-sensitivity to acetylsalicylic acid, phenylacetylic acid derivatives, and other nonsteroidal anti-inflammatory drugs. When treating patients with a history of hypersensitivity to these drugs, the use of such medications should be avoided.

Hypersensitivity in some individuals.

The use of topical NSAIDs may lead to the development of keratitis. In some susceptible patients, prolonged use of topical NSAIDs may cause epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration, or corneal perforation. These adverse events carry a risk of vision loss. Patients with signs of corneal epithelial breakdown should immediately discontinue use of the drug and remain under medical supervision until the condition of the cornea normalizes.

Postmarketing experience.

Experience with topical NSAIDs shows that patients with complications following ophthalmic surgery, corneal denervation, corneal epithelial defects, diabetes mellitus, superficial eye diseases (e.g., “dry eye” syndrome), rheumatoid arthritis, and patients who have undergone repeated surgical procedures within a short period of time are at increased risk of developing adverse reactions affecting the cornea.

NSAIDs may prolong bleeding time due to impaired platelet aggregation. The use of topical NSAIDs in combination with ophthalmic surgeries may increase bleeding in ocular tissues (including in the anterior chamber of the eye [hyphema]). Broxinac should be used with caution in patients with a history of bleeding tendency or in patients receiving other medications that may prolong blood clotting time.

In rare cases, an exacerbation of the inflammatory response—such as macular edema—has been observed following discontinuation of bromphenac after cataract surgery.

Eye infections.

Acute eye infections may be masked by the topical application of anti-inflammatory medications.

Contact lenses.

Patients should not wear contact lenses while using Broxinac.

The use of topical NSAIDs within 24 hours before eye surgery and for 14 days after ophthalmic surgery increases the risk and severity of adverse reactions involving the cornea.

Patients should be advised not to touch the tip of the dropper or allow it to come into contact with any surface, as this may lead to contamination of the vial’s contents.

Use during pregnancy or breastfeeding.

Pregnancy

The safety of 0.09% bromphenac eye drops during pregnancy has not been studied. The drug may be used if the expected benefit to the mother outweighs the potential risk to the fetus.

Prescribing this medication during the third trimester of pregnancy should be avoided due to the known effects of drugs that inhibit prostaglandin biosynthesis on the fetal cardiovascular system (closure of the ductus arteriosus).

Breastfeeding

Caution should be exercised when administering this drug to women.

Fertility.

Animal studies have shown no effect of bromfenac on fertility. Furthermore, the systemic exposure to bromfenac is negligible; therefore, pregnancy testing and contraceptive measures are not required.

Effect on reaction time when driving or operating machinery.

This medication has a negligible effect on the ability to drive or operate machinery. Temporary blurred vision may occur after administration; therefore, it is recommended to wait until vision has fully returned before driving or operating machinery.

Dosage and Administration

Adults (including elderly patients)

For the treatment of postoperative inflammation and pain relief in patients following cataract extraction, instillation of 1 drop into the conjunctival sac once daily is recommended. Treatment should begin 1 day before surgery and continue for the first 14 days of the postoperative period (including the day of surgery).

For the treatment of non-infectious inflammatory diseases of the anterior segment of the eye, it is recommended to instill 1 drop of the medication into the conjunctival sac twice daily. The course of treatment is determined by the physician depending on the severity of the condition.

When using multiple topical ophthalmic medications, the interval between administrations should be at least 5 minutes.

Remove contact lenses before instilling the eye drops. They may be reinserted 15 minutes after instillation.

If a dose is missed, apply the medication as soon as possible at the dose specified in the instructions. If nearly 24 hours have passed since the missed dose, apply the medication at the next scheduled time without doubling the dose to make up for the missed one.

For elderly patients, the dosing regimen is the same as for younger patients.

Children

Under 18 years of age (the safety and efficacy of the medication in children have not been studied).

Overdose

Do not instill additional drops until it is time for the next scheduled dose.

In case of overdose, eye irritation and conjunctival hyperemia may occur.

Treatment is symptomatic. In case of overdose, rinse the eyes with warm water.

There is virtually no risk of adverse effects from accidental ingestion. Swallowing the contents of a 5-mL bottle corresponds to an oral dose of less than 5 mg of bromfenac, which is 30 times lower than the daily dose of the oral bromfenac preparation previously used. If the medication is accidentally ingested, drink a large amount of liquid immediately to reduce the concentration of the medication in the stomach and consult a doctor.

Side Effects

Ocular side effects:

When taking the medication once daily: discomfort and unusual sensations in the eyes, eye irritation, pain, itching, and a burning sensation in the eyes, redness of the eyes, conjunctival hyperemia, and inflammation of the iris.

When using the medication twice daily:

Decreased visual acuity, retinal hemorrhages, corneal edema, photophobia, bleeding from the eyelid vessels, fundus exudates, corneal erosion, conjunctivitis, blepharitis, irritation, transient eye pain, superficial punctate keratitis, itching, blurred vision, eyelid edema, and ocular discharge.

There have been isolated postmarketing reports of corneal perforation, corneal thinning, corneal epithelial erosion, corneal ulceration, scleromalacia, corneal infiltrates, corneal scarring, and corneal disorders.

Nervous system disorders: headache.

Respiratory system: nosebleeds, cough, nasal discharge, asthma attacks.

General disorders: facial edema, contact dermatitis.

Shelf life

2 years.

Shelf life after opening the vial: 28 days.

Do not use after the expiration date printed on the package.

Storage conditions

Store at a temperature not exceeding 25 °C in the original packaging.

Keep out of reach of children.

Packaging

1.7 mL of eye drops in a bottle with a dropper, in a cardboard package.

Dispensing Category

By prescription only.